FCGRT and autoimmune thrombocytopenic purpura: While administration of high IgG doses have been postulated to saturate the FcRn receptors and thereby accelerate the degradation of circulating pathogenic autoantibodies [14–16], a recent study in a murine model of ITP (immune thrombocytopenia) reported that IVIg was still effective in increasing platelet counts in the absence of FcRn [17].